Total Hip Replacement, Total Knee Replacement
Conditions
Keywords
elective, primary unilateral
Brief summary
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs. Leg and lung blood clots occur commonly after patients have surgery to replace a hip or knee joint. These clots often occur while patients are in bed in the hospital after hip or knee joint surgery. The purpose of this study is to test if different dose strengths (amount of drug in the capsules) of LY517717 can prevent blood clots from forming and to determine if LY517717 is safe. This study will compare LY517717 to enoxaparin, another blood thinner. Enoxaparin is one of the standard medications given after hip or knee joint surgery.
Interventions
DRUGLY517717
DRUGenoxaparin
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Are scheduled for total knee or hip replacement surgery (only one side, first time joint replacement) * Are at least 18 years of age and no more than 75 years of age. * Have a body weight more than 50 kg and less than 120 kg. * Sign an approved Eli Lilly and Company informed consent document.
Exclusion criteria
* Have had hip or knee replacement surgery in the non-surgical leg or any surgical procedure in the surgical leg within 6 months prior to enrollment. * Other surgeries (brain, spinal cord, eye within 12 months; chest or abdominal surgery within 1 month). * Have taken drugs that might increase possibility of bleeding. * Other risk factors for bleeding (bleeding disorders, abnormal results on blood tests, ulcers) * Increased risk for blood clots.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of LY517717 to enoxaparin in the prevention of VTEs measured by the proportion of patients with VTE event (DVT and/or PE) as confirmed by bilateral venography or on clinical assessment | end of study drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability, major and minor bleeding, death due to VTE, effect on QTc duration, AEs and SAEs, hepatobiliary and other safety lab parameters | baseline, daily during therapy, at follow up visit |
| Pharmacokinetics and pharmacodynamics | predose, daily during therapy |
| Compare the effect of LY517717 versus enoxaparin measured by DVT, Proximal DVT, Distal DVT and PE | end of study drug administration |
| Compare the effect of LY517717 versus enoxaparin with confirmed VTE | end of study drug administration |
| Compare the effect of LY517717 versus enoxaparin measured by all confirmed VTEs and /or clinically suspected and confirmed VTE | through follow up |
Countries
Australia, Austria, Belgium, Czechia, Germany, Hungary, Italy, Poland
Outcome results
None listed